Drug delivery embolization systems: a physician's perspective

Bibliography

• Ferlay J, Shin HR, Bray F, GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC CancerBase No. 10. 2010. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr
   Google Scholar
• Manfredi S, Lepage C, Hatem C, Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9
   PubMed Web of Science ®Google Scholar
• Gatta G, Capocaccia R, Sant M, Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut 2000;47:533-8
   PubMed Web of Science ®Google Scholar
• Ksienski D, Woods R, Speers C, Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC, Ann Surg Oncol 2010;8:3085-93
   Google Scholar
• Poston G, Adam R, Alberts S, OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005;23:7125-34
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Global Cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006;26:142-52
   PubMed Web of Science ®Google Scholar
• Kassahun WT, Fangmann J, Harms J, Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Tranplant 2006;4:549-58
   PubMedGoogle Scholar
• Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006;5:495-500
   PubMedGoogle Scholar
• Sotiropoulus GC, Lang H, Frilling A, Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary speciality center and systematic review of the literature. Hepatogastroenterology 2006;53:322-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9
   PubMed Web of Science ®Google Scholar
• van Persijin van Meerten E, Gelderbrom H, Bloem JL. RECIST revised: implications fort he radiologist. A review article on the modified RECIST guidelines. Eur Radiol 2010;20:1456-67
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30
   PubMed Web of Science ®Google Scholar
• Sala M, Llovet JM, Vilana R, Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60
   PubMed Web of Science ®Google Scholar
• Camma C, Di Marco V, Orlando A, Treatment of hepatocellular carcinoma in compensated cirrhosis with radiofrequency thermal ablation: a prospective study. J Hepatol 2005;42:535-40
   PubMed Web of Science ®Google Scholar
• Forner A, Ayuso C, Varela M, Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer 2009;115:616-23
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711
   PubMed Web of Science ®Google Scholar
• Yamada R, Sato M, Kawabata M, Hepatic artery embolisation in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401
   PubMed Web of Science ®Google Scholar
• Matsui K, tomoe T, Teragima S et al. Clinical study on continuous 5-FU infusion for the treatment of primary liver cancer. Gan No Rinsho 1970;16:43-7
   PubMedGoogle Scholar
• Nakakuma K, Tashiro S, Hiraoka T, Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983;52:2193-200
   PubMed Web of Science ®Google Scholar
• Nakakuma K, Tashiro S, Hiraoka T, Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985;154:15-17
   PubMed Web of Science ®Google Scholar
• Camma C, Schepis F, Orlando A, Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C, Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30(1):6-25
   PubMed Web of Science ®Google Scholar
• Li X, Feng GS, Zheng CS, Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effects of transcatheter arterial chemoembolisation therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004;10:2878-82
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, Randomized controlled trial of transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71
   PubMed Web of Science ®Google Scholar
• Takayasu K, Arii S, Ikai I, Prospective cohort study of transarterial chemoembolisation for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9
   PubMed Web of Science ®Google Scholar
• Raoul JL, Sangro B, Forner A, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212-20
   PubMed Web of Science ®Google Scholar
• Georgiades CS, Hong K, D'Angelo M, Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653-9
   PubMed Web of Science ®Google Scholar
• Gomes AS, Rosove MH, Rosen PJ, Triple-drug transcatheter arterial chemoembolisation in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients. AJR 2009;193:1665-71
   PubMed Web of Science ®Google Scholar
• Covey AM, Maluccio MA, Schubert J, Particle embolisation of recurrent hepatocellular carcinoma after hepatectomy. Cancer 2006;106:2181-9
   PubMed Web of Science ®Google Scholar
• Amesur NB, Zajko AB, Carr BI. Chemo-embolisation for unresectable hepatocellular carcinoma with different sizes of embolisation particles. Dig Dis Sci 2008;53:1400-4
   PubMed Web of Science ®Google Scholar
• Nicolini A, Fasani P, Manini M, Transarterial embolisation with microspheres in the treatment of monofocal HCC. Dig Liv Dis 2009;41:143-9
   Web of Science ®Google Scholar
• Bruix J, Llovet JM, Castells A, Transarterial embolisation versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83
   PubMed Web of Science ®Google Scholar
• Fu Y, Kao WJ. Drug release kinetics and transport mechanisms and degradable polymeric delivery systems. Expert Opin drug Deliv 2010;7:429-44
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81
   PubMed Web of Science ®Google Scholar
• Namur J, Wassef M, Millot JM, Drug-eluting beads for liver embolization. Concentration of doxorubicin in tissue and in beads in a pig model. JVIR 2010;4:259-67
   Google Scholar
• Taylor RR, Tang Y, Gonzalez MV, Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007;30:7-14
   PubMed Web of Science ®Google Scholar
• Lewis AL, Taylor RR, Hall B, Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolisation. J Vasc Interv Radiol 2006;17:1335-43
   PubMed Web of Science ®Google Scholar
• Lee KH, Liapi E, Cornell C, Doxorubicin-loaded Quadrasphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 2010;33:576-82
   PubMed Web of Science ®Google Scholar
• Jordan O, Denys A, De Baere T, Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC-Bead and Hepasphere loaded with doxorubicin and irinotecan. JVIR 2010;21:1084-90
   Google Scholar
• Sottani C, Leoni E, Porro B, Validation of an LC-MS/MS method for the determination of epirubicin in human serum of patients undergoing drug eluting microsphere-transarterial chemoembolization (DEM-TACE). J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3543-8
   PubMed Web of Science ®Google Scholar
• Hong K, Kobeiter H, Georgiades CS, Effects of the type of embolisation particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol 2005;16:1711-17
   PubMed Web of Science ®Google Scholar
• Lee KH, Liapi E, Vossen JA, Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. JVIR 2008;19:1490-6
   Google Scholar
• Malagari K, Chatzimichael K, Alexopoulou E, Transarterial chemoembolisation of unresectable hepatocellular carcinoma with drug eluting beads: result of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008;31:269-80
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52
   PubMed Web of Science ®Google Scholar
• Nicolini A, Martinetti L, Crespi S, Transarterial chemoembolisation with epirubicin-eluting beads versus transarterial embolisation before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:327-32
   PubMed Web of Science ®Google Scholar
• Malagari K, Pomoni M, Keleki A, Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541-51
   PubMed Web of Science ®Google Scholar
• Khankan AA, Osuga K, Hori S, Embolic effects of superabsorbent polymer microspheres in rabbit renal model: comparison with tris-acryl gelatin microspheres and polyvinyl alcohol. Radiat Med 2004;22:384-90
   PubMedGoogle Scholar
• Grosso M, Vignali C, Quaretti P, Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicenter study. Cardiovasc Intervent Radiol 2008;31:1141-9
   PubMed Web of Science ®Google Scholar
• Poon RT. Differentiating early and late recurrence after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Onc 2009;16:792-4
   PubMed Web of Science ®Google Scholar
• Lencioni R, Crocetti L, Petruzzi P, Doxorubicin-eluting beads enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008;49:217-22
   PubMed Web of Science ®Google Scholar
• Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int 2010;30:741-9
   PubMed Web of Science ®Google Scholar
• Wang B, Xu H, Gao ZQ, Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter chemoembolisation. Acta Radiol 2008;49:523
   PubMed Web of Science ®Google Scholar
• Lao OB, Weissman J, Perkins JD. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clin Transplant 2009;23:874-81
   PubMed Web of Science ®Google Scholar
• Fordy C, Burke D, Earlam S, Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60
   PubMed Web of Science ®Google Scholar
• Tellez C, Benson AB III, Lyster MT, Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998;82:1250-9
   PubMed Web of Science ®Google Scholar
• Stuart K. Chemoembolization in the management of liver tumors. Oncologist 2003;8:425-37
   PubMed Web of Science ®Google Scholar
• Martin RCG, Robbins K, Tomalty D, Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009;7:80-91
   PubMed Web of Science ®Google Scholar
• Aliberti C, Tilli M, Benea G, Transarterial chemoembolisation (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2006;26:3793-5
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Aliberti C, Turrisi G, Intra-arterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007;21:1085-91
   PubMed Web of Science ®Google Scholar
• Martin RCG, Joshi J, Robbins K, Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Sur Oncol 2011;18:192-8
   PubMed Web of Science ®Google Scholar
• Martin RCG, Joshi J, Robbins K, Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multiinstitutional registry. J Oncol 2009;2009:539795
   PubMedGoogle Scholar
• Bower M, Metzger T, Robbins K, Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HBP 2010;12:31-6
   Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
   PubMed Web of Science ®Google Scholar